Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients
- 14 July 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (12), 2811-2820
- https://doi.org/10.1080/10428194.2020.1783444
Abstract
While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2–4.9; p = .02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5–1.1; p = .099). AlloHCT in CP2 + [HR = 2.0 (0.8–4.9), p = .13] and AP [HR = 1.1 (0.6–2.1); p = .80] is less clear and should be determined on a case-by-case basis.Keywords
Funding Information
- National Cancer Institute (5U24CA076518)
- National Heart, Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- NHLBI (4U10HL069294)
- NCI
- Health Resources and Services Administration (HHSH250201200016C)
- Actinium Pharmaceuticals, Inc. (N00014-17-1-2388, N0014-17-1-2850)
- Amgen, Inc.
- Amneal Biosciences
- Angiocrine Bioscience, Inc.
- Anonymous donation to the Medical College of Wisconsin
- Astellas Pharma US
- Atara Biotherapeutics, Inc.
- Be The Match Foundation
- Bluebird Bio, Inc.
- Bristol Myers Squibb Oncology
- Celgene Corporation
- Cerus Corporation
- Chimerix, Inc.
- Fred Hutchinson Cancer Research Center
- Gamida Cell Ltd.
- Gilead Sciences, Inc.
- HistoGenetics, Inc.
- Immucor
- Incyte Corporation
- Janssen Scientific Affairs, LLC
- Jazz Pharmaceuticals, Inc.
- Juno Therapeutics
- Karyopharm Therapeutics, Inc.
- Kite Pharma, Inc.
- Medac, GmbH
- MedImmune
- The Medical College of Wisconsin
- Mediware
- Merck & Co, Inc.
- Mesoblast
- MesoScale Diagnostics, Inc.
- Millennium, the Takeda Oncology Co.
- Miltenyi Biotec, Inc.
- National Marrow Donor Program
- Neovii Biotech NA, Inc.
- Novartis Pharmaceuticals Corporation
- Otsuka Pharmaceutical Co, Ltd. – Japan
- PCORI
- Pfizer, Inc
- Pharmacyclics, LLC
- PIRCHE AG
- Sanofi Genzyme
- Seattle Genetics
- Shire
- Spectrum Pharmaceuticals, Inc.
- St. Baldrick’s Foundation
- Sunesis Pharmaceuticals, Inc.
- Swedish Orphan Biovitrum, Inc.
- Takeda Oncology
- Telomere Diagnostics, Inc
- University of Minnesota
- Center for Strategic Scientific Initiatives.
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases (4U10HL069294)
- NHLBI
- NCI (HHSH250201200016C)
- Health Resources and Services Administration (N00014-17-1-2388, N0014-17-1-2850)
- Actinium Pharmaceuticals, Inc.
This publication has 30 references indexed in Scilit:
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemiaInternational Journal of Hematology, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2006
- Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyBlood, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2003
- Advanced-phase chronic myeloid leukemiaSeminars in Hematology, 2003
- Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phaseBlood, 2003
- Advanced-phase chronic myeloid leukemiaSeminars in Hematology, 2003
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeThe New England Journal of Medicine, 2001